Filed pursuant to Rule 424(b)(3)
Registration Statement No. 333-267031
Prospectus Supplement No. 3
(To Prospectus dated
March 21, 2023)
43,414,721 SHARES OF COMMON STOCK
OF
AKILI, INC.
This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2023 (as supplemented or amended from time to time, the
Prospectus), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-267031). Capitalized terms used in this prospectus
supplement and not otherwise defined herein have the meanings specified in the Prospectus.
This prospectus supplement is being filed to update, amend and
supplement the information included in the Prospectus with specified information contained or incorporated by reference in our Current Report on Form 8-K filed with the Securities and Exchange Commission on
May 11, 2023, which is set forth below.
This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read
in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information
contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.
Akili, Inc.s common stock is quoted
on the Nasdaq Capital Market under the symbol AKLI. On May 10, 2023, the closing price of our common stock was $1.25.
INVESTING IN OUR SECURITIES
INVOLVES CERTAIN RISKS. SEE RISK FACTORS BEGINNING ON PAGE 16 OF THE PROSPECTUS.
Neither the Securities and Exchange Commission nor any
state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is May 11, 2023